Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and cardiometabolic diseases, aiming for innovative treatments.

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion, granting Lilly access to its AI-driven platform to discover and develop obesity drugs.

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new small molecule obesity medications for Lilly.

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven platform.

The latest obesity bet from Eli Lilly and Co. involves a Boston biotech based out of the pharma giant’s new Fort Point R&D center.

Eli Lilly has entered into a deal worth up to $1.3 billion with drug discovery company Superluminal Medicines to advance small molecule therapeutics relevant to cardiometabolic diseases and obesity, Superluminal said on Thursday.